1.
Cancer Discov
; 13(12): 2515-2524, 2023 12 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38084090
RESUMO
SUMMARY: Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.